Aethlon Medical (AEMD) Q1 2025 earnings summary

Executive summary

• Advanced Hemopurifier clinical trials in Australia with two ethics approvals; patient enrollment expected to begin between September and October 2024.

• Ongoing COVID-19 trial in India, with one patient treated to date and continued evaluation of trial continuation.

• Achieved significant cost reductions and improved cash position, alleviating prior going concern doubts.

• Closed a $4.7M public equity offering in May 2024, with additional warrant exercises raising $1.8M.

• Focused on developing the Hemopurifier for cancer and viral infections, with preclinical evidence supporting its effectiveness.

Financial highlights

• Operating expenses for the quarter ended June 30, 2024, were $2.6 million, down 24% from $3.4 million in the prior year quarter, mainly due to lower general/admin expenses and professional fees.

• Net loss decreased to $2.57 million in Q2 2024 from $3.3 million in Q1 FY2024 and $3.28 million in the prior year.

• Cash and equivalents at June 30, 2024, were $9.1 million, up from $5.44 million at March 31, 2024.

• Weighted average shares outstanding increased to 7.5 million from 2.4 million year-over-year due to equity issuances.

• Excluding a $300,000 employee termination provision, operating expenses decreased by over $1 million quarter-over-quarter.

Outlook and guidance

• Management expects existing cash to fund operations for at least 12 months from the report date.

• Further expense reductions expected from switching to less expensive law and accounting firms, though clinical trial and manufacturing expenses will rise as Australian and Indian trials ramp up.

• Patient enrollment for Australian oncology trials expected to begin in September–October 2024, with potential expansion to additional sites in Australia and India by year-end.

• Next earnings call scheduled for November 2024, following Q2 results.

• Plans to access equity markets for additional capital as needed.